June 12 (Reuters) - Imv Inc IMV.TO :
* NEW PHASE 2 CLINICAL TRIAL RESULTS CONTINUE TO DEMONSTRATE POTENTIAL CLINICAL BENEFIT OF IMV'S DPX-SURVIVAC IN COMBINATION WITH MERCK'S KEYTRUDA IN PATIENTS WITH DLBCL
* IMV INC - COMPLETE RADIOLOGIC RESPONSES LINKED TO T CELL ACTIVITY OBSERVED IN TWO OF FIRST SIX EVALUABLE PATIENTS
* IMV - AT FIRST "ON TREATMENT" ASSESSMENT, FIVE OF FIRST SIX PATIENTS DEMONSTRATED CLINICAL BENEFIT, INCLUDING FOUR PATIENTS WITH TUMOR REGRESSIONS
* IMV INC - TREATMENT COMBINATION APPEARS TO BE WELL-TOLERATED WITH ONLY 2 SERIOUS ADVERSE EVENTS RELATED TO TREATMENT